Clinical Trials Logo

Bioavailability Study clinical trials

View clinical trials related to Bioavailability Study.

Filter by:
  • None
  • Page 1

NCT ID: NCT04688008 Completed - Clinical trials for Bioavailability Study

Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations

Start date: September 18, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the relative bioavailability of early phase and late phase hetrombopag olamine formulations in healthy Chinese adult subjects under fasting conditions. The secondary objective of the study is to evaluate the safety of hetrombopag olamine in healthy Chinese adult subjects.

NCT ID: NCT03972462 Completed - Clinical trials for Bioavailability Study

NPC-12G Gel 0.2% Sirolimus PK Bridging Study

Start date: May 31, 2019
Phase: Phase 1
Study type: Interventional

This study is designed to describe the relative systemic bioavailability of topical and oral sirolimus formulations.

NCT ID: NCT03334084 Completed - Clinical trials for Bioavailability Study

A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects

Start date: October 11, 2017
Phase: Phase 1
Study type: Interventional

The study is a Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation With an Intravenous Formulation of ARGX-113 in Healthy Male Subjects

NCT ID: NCT02883439 Withdrawn - Clinical trials for Bioavailability Study

Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate

BIODYMF
Start date: August 2016
Phase: N/A
Study type: Interventional

The aim of this study is to investigate and to compare the bioavailability of MP29-02 and fluticasone propionate in nasal tissue after nasal application. This may provide a rational basis for the use of 1 puff per nostril dosage regimen of the drugs. Clinical experience has demonstrated the efficacy of the twice-daily treatment; however, so far, no data are available on the local tissue concentrations of MP29-02 after topical application.